Clodronate as a Therapeutic Strategy against Osteoarthritis
Authors:
Open Access
- 13 December 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (12) , 2696
Abstract
Osteoarthritis (OA), the most prevalent musculoskeletal pathology, is mainly characterized by the progressive degradation of articular cartilage due to an imbalance between anabolic and catabolic processes. Consequently, OA has been associated with defects in the chondrocitic differentiation of progenitor stem cells (PSCs). In addition, SOX9 is the transcription factor responsible for PSCs chondrogenic commitment. To evaluate the effects of the non-amino bisphosphonate clodronate in OA patients we investigated SOX9 gene expression in circulating progenitor cells (CPCs) and in an in vitro OA model. We evaluated pain intensity, mental and physical performance in OA patients, as well as serum biomarkers related to bone metabolism. In addition, in order to improve therapeutic strategies, we assayed nanoparticle-embedded clodronate (NPs-clo) in an in vitro model of chondrogenic differentiation. Our data showed upregulation of SOX9 gene expression upon treatment, suggesting an increase in chondrocytic commitment. Clodronate also reduced osteoarticular pain and improved mental and physical performance in patients. Furthermore, NPs-clo stimulated SOX9 expression more efficaciously than clodronate alone. Clodronate may therefore be considered a good therapeutic tool against OA; its formulation in nanoparticles may represent a promising challenge to counteract cartilage degeneration.Keywords
This publication has 35 references indexed in Scilit:
- Vitamin D and Its Role in Skeletal MuscleCalcified Tissue International, 2012
- Role of proinflammatory cytokines in the pathophysiology of osteoarthritisNature Reviews Rheumatology, 2010
- Effect of bisphosphonates on nitric oxide production by inflammatory activated chondrocytes.2008
- Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivoProceedings of the National Academy of Sciences, 2005
- The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClinical and Experimental Immunology, 2004
- New Insights Into the Molecular Mechanisms of Action of BisphosphonatesCurrent Pharmaceutical Design, 2003
- The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosisArthritis & Rheumatism, 2001
- Sox9 is required for cartilage formationNature Genetics, 1999
- SOX9 Binds DNA, Activates Transcription, and Coexpresses with Type II Collagen during Chondrogenesis in the MouseDevelopmental Biology, 1997
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996